Neumora (NMRA) insider purchase: 1,915,700 shares at $2.61
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Neumora Therapeutics (NMRA) insider filing: Director and 10% owner Kristina Burow reported a purchase of 1,915,700 shares of common stock at $2.61 on 10/27/2025, recorded as an indirect transaction by ARCH Venture Fund XII, L.P.
Following the transaction, reported beneficial holdings include: 6,046,907 shares indirectly via ARCH Venture Fund XII, L.P.; 1,387,228 via ARCH Venture Fund VII, L.P.; 2,321,566 via ARCH Venture Fund VIII Overage, L.P.; 12,205,379 via ARCH Venture Fund X, L.P.; 11,886,758 via ARCH Venture Fund X Overage, L.P.; and 47,717 shares held directly.
Positive
- None.
Negative
- None.
Insights
Insider Form 4 shows a sizable purchase at $2.61; neutral impact.
The filing lists a buy of 1,915,700 NMRA shares at $2.61 on 10/27/2025, attributed to ARCH Venture Fund XII and reported by Director/10% owner Kristina Burow. This increases reported indirect holdings across several ARCH funds plus a small direct position.
The business takeaway is administrative: it updates beneficial ownership and reflects a completed open-market purchase. Actual market impact depends on broader ownership and liquidity, which are not detailed in the excerpt.
Insider Trade Summary
Net Buyer: 1,915,700 shares ($4,999,977)
Net Buy
6 txns
Insider
Burow Kristina
Role
Director, 10% Owner
Bought
1,915,700 shs ($5.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,915,700 | $2.61 | $5.00M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 6,046,907 shares (Indirect, By ARCH Venture Fund XII, L.P.);
Common Stock — 47,717 shares (Direct)
Footnotes (1)
- Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
FAQ
What did NMRA disclose in this Form 4?
A purchase of 1,915,700 NMRA common shares at $2.61 on 10/27/2025, reported by Director/10% owner Kristina Burow and attributed to ARCH Venture Fund XII, L.P.
What is the relationship of the reporting person to NMRA?
The reporting person is a Director and 10% Owner.
Was the transaction reported as indirect or direct ownership?
The 1,915,700-share purchase was reported as indirect via ARCH Venture Fund XII, L.P.; a separate 47,717 shares are held directly.
Who signed the NMRA Form 4?
Signed for Kristina Burow by /s/ Mark McDonnell as Attorney-in-Fact, dated 10/29/2025.